• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by STAAR Surgical Company

    4/24/25 5:03:30 PM ET
    $STAA
    Ophthalmic Goods
    Health Care
    Get the next $STAA alert in real time by email
    DEFA14A 1 staa_defa_14a_notice_202.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒

     

     

     

     

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material under §240.14a-12

     

    STAAR Surgical Company

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0‑11.

     


     

    img217286323_0.jpg

     


     

    Your Vote Counts! STAAR SURGICAL COMPANY 2025 Annual Meeting Vote by June 17, 2025 11:59 PM ET STAAR SURGICAL COMPANY 25510 COMMERCENTRE DRIVE LAKE FOREST, CA 92630 ATTN: CORPORATE SECRETARY V74213-P32097 You invested in STAAR SURGICAL COMPANY and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on June 18, 2025. Get informed before you vote View the Form 10-K and Notice and Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 4, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 18, 2025 8:30 AM PDT Virtually at: www.virtualshareholdermeeting.com/STAA2025 *Please check the meeting materials for any special requirements for meeting attendance.

    img217286323_1.jpg

    Vote at www.ProxyVote.comTHIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters Voting Items Board Recommends 1. Election of Directors Nominees: 01) Arthur C. Butcher 02) Stephen C. Farrell 03) Wei Jiang 04) Louis E. Silverman 05) Elizabeth Yeu, MD 06) Lilian Y. Zhou 2. Ratification of the appointment of BDO USA, P.C. as our independent registered public accounting firm for the year ending January 2, 2026. 3. Non-binding advisory vote to approve the compensation of our named executive officers. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the Annual Meeting of Shareholders or any postponement or adjournment thereof. For For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V74214-P32097

     


    Get the next $STAA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STAA

    DatePrice TargetRatingAnalyst
    4/21/2025$17.00Equal Weight
    Wells Fargo
    2/12/2025Buy → Hold
    Jefferies
    2/12/2025$45.00 → $17.00Outperform → Neutral
    Mizuho
    2/12/2025Buy → Neutral
    BTIG Research
    2/12/2025Outperform → Mkt Perform
    William Blair
    7/15/2024$50.00 → $37.00Equal-Weight → Underweight
    Morgan Stanley
    6/11/2024$46.00Neutral → Buy
    BTIG Research
    3/11/2024$30.00 → $50.00Hold → Buy
    Stifel
    More analyst ratings

    $STAA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Broadwood Partners, L.P. bought $2,866,428 worth of shares (187,227 units at $15.31) (SEC Form 4)

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      4/10/25 7:00:22 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • Large owner Broadwood Partners, L.P. bought $13,627,504 worth of shares (845,220 units at $16.12) (SEC Form 4)

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      4/7/25 8:28:12 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • Large owner Broadwood Partners, L.P. bought $941,285 worth of shares (53,969 units at $17.44) (SEC Form 4)

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      4/2/25 8:33:34 PM ET
      $STAA
      Ophthalmic Goods
      Health Care

    $STAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Development Officer Michna Magda covered exercise/tax liability with 1,675 shares, decreasing direct ownership by 10% to 14,444 units (SEC Form 4)

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      5/14/25 8:41:13 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by Director Silverman Lou

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      5/13/25 6:04:36 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by Director Jiang Wei

      4 - STAAR SURGICAL CO (0000718937) (Issuer)

      5/13/25 6:02:43 PM ET
      $STAA
      Ophthalmic Goods
      Health Care

    $STAA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $STAA
    SEC Filings

    See more
    • Wells Fargo initiated coverage on STAAR Surgical with a new price target

      Wells Fargo initiated coverage of STAAR Surgical with a rating of Equal Weight and set a new price target of $17.00

      4/21/25 8:38:55 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical downgraded by Jefferies

      Jefferies downgraded STAAR Surgical from Buy to Hold

      2/12/25 11:13:24 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical downgraded by Mizuho with a new price target

      Mizuho downgraded STAAR Surgical from Outperform to Neutral and set a new price target of $17.00 from $45.00 previously

      2/12/25 7:11:03 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - STAAR SURGICAL CO (0000718937) (Filer)

      5/16/25 7:00:09 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by STAAR Surgical Company

      10-Q - STAAR SURGICAL CO (0000718937) (Filer)

      5/7/25 4:11:47 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STAAR SURGICAL CO (0000718937) (Filer)

      5/7/25 4:02:55 PM ET
      $STAA
      Ophthalmic Goods
      Health Care

    $STAA
    Financials

    Live finance-specific insights

    See more
    • STAAR Surgical Announces $30 Million Share Repurchase Authorization

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. "Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth," said Stephen C. Farrell, Chief Executive Officer of STAAR Surgical. "With a strong balance sheet, no debt, and clear progress in our cost optimization and strategic priorities, we

      5/16/25 7:00:00 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Reports First Quarter 2025 Results

      China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin at 65.8% vs. 78.9% year ago due

      5/7/25 4:01:00 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance

    $STAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company

      SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

      9/6/24 9:51:09 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

      SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

      2/13/24 5:14:04 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

      SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)

      1/26/24 9:19:42 AM ET
      $STAA
      Ophthalmic Goods
      Health Care

    $STAA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STAAR Surgical Announces Participation in Upcoming Investor Conferences

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2025 Virtual Ophthalmology Forum Date: Tuesday, May 27, 2025 Format: Meetings and Webcast Fireside Chat Webcast: 2:00 PM ET, Webcast Link Wells Fargo 2025 West Coast Bus Tour Date: Thursday, May 29, 2025 Location: Laguna Beach, CA Format: Fireside Chat; No Webcast William Blair 45th Annual Growth Stock Conference Date: Wednesday, June 4, 2025 Location: Chicago, IL Format: Meetings and Webcast Slide Presentation Webcast: 9:40 AM ET, Webcast

      5/22/25 7:00:00 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Announces $30 Million Share Repurchase Authorization

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. "Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth," said Stephen C. Farrell, Chief Executive Officer of STAAR Surgical. "With a strong balance sheet, no debt, and clear progress in our cost optimization and strategic priorities, we

      5/16/25 7:00:00 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Reports First Quarter 2025 Results

      China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin at 65.8% vs. 78.9% year ago due

      5/7/25 4:01:00 PM ET
      $STAA
      Ophthalmic Goods
      Health Care

    $STAA
    Leadership Updates

    Live Leadership Updates

    See more
    • STAAR Surgical Announces Leadership Transition

      Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to

      2/26/25 4:45:00 PM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

      New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501408389/en/Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo:

      5/1/24 7:00:00 AM ET
      $STAA
      Ophthalmic Goods
      Health Care
    • STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024. "Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry," said Aimee Weisner, Chair

      3/12/24 7:00:00 AM ET
      $STAA
      Ophthalmic Goods
      Health Care